9 Chapter 12Figure 12.1 Extranodal natural killer (NK)/T‐cell lymphoma. (A) Clinical pre...Figure 12.2 The incidence of extranodal natural killer/T‐cell lymphoma among...Figure 12.3 Summary of the pathways involved in the pathogenesis of extranod...Figure 12.4 Positron emission tomography scan showing adrenal gland localiza...Figure 12.5 Extranasal localization of extranodal natural killer/T‐cell lymp...
10 Chapter 14Figure 14.1 Dysregulated cell signaling pathways in large granular lymphocyt...Figure 14.2 Characteristics of immune cells in large granular lymphocyte leu...
11 Chapter 15Figure 15.1 Dural involvement by peripheral T‐cell lymphoma not otherwise sp...Figure 15.2 (a) Skin manifestations of gamma–delta T cell lymphoma. Lesions ...Figure 15.3 Primary cutaneous gamma–delta T‐cell lymphoma involving deep der...Figure 15.4 Nodal involvement by a primary cutaneous gamma delta T‐cell Lymp...Figure 15.5 Dural involvement by peripheral T‐cell lymphoma, NOS with gamma ...
12 Chapter 16Figure 16.1 Enteropathy‐associated T‐cell lymphoma. (a) A dense infiltrate o...Figure 16.2 Refractory celiac disease (RCD). (a) Duodenal biopsy from a pati...Figure 16.3 Monomorphic epitheliotropic intestinal T‐cell lymphoma. The lami...
13 Chapter 18Figure 18.1 Mycosis fungoides; hypopigmented and erythematous patches on the...Figure 18.2 Mycosis fungoides with poikilodermatous features.Figure 18.3 Folliculotropic mycosis fungoides; indurated plaques and tumors ...Figure 18.4 Sézary syndrome; diffuse erythroderma with scaling and leonine f...Figure 18.5 Subcutaneous panniculitis‐like T‐cell lymphoma; indurated erythe...Figure 18.6 Histopathologic changes of early mycosis fungoides. The epidermi...Figure 18.7 Immunophenotypic changes in mycosis fungoides. The lymphoid popu...Figure 18.8 Mycosis fungoides with large‐cell transformation. In this biopsy...Figure 18.9 Histopathologic changes of folliculotropic mycosis fungoides. A ...Figure 18.10 Histopathologic changes in Sézary syndrome. The infiltrate is m...Figure 18.11 Histopathologic changes in aggressive epidermotropic CD8+ T‐cel...Figure 18.12 Histopathologic changes in cutaneous CD4+ small to medium T‐cel...Figure 18.13 Immunophenotypic findings in cutaneous CD4+ small to medium T‐c...Figure 18.14 Treatment of patients with mycosis fungoides (Stages I–III).Figure 18.15 Treatment of patients with mycosis fungoides (Stage IV).
14 Chapter 19Figure 19.1 Histopathological findings on lymph node biopsy of systemic Epst...Figure 19.2 Histopathological findings on lymph node biopsy of systemic Epst...
15 Chapter 20Figure 20.1 Overall survival for patients with aggressive peripheral T‐cell ...Figure 20.2 Overall survival for the intention‐to‐treat population. The haza...
16 Chapter 22Figure 22.1 The impact of time. Survival curves of patients based on time pe...Figure 22.2 Survival curve of patients who received novel therapies compared...Figure 22.3 Progression‐free survival stratified by consolidative strategy. ...Figure 22.4 Meta‐analysis of the hazard ratios of overall survival in patien...
17 Chapter 26Figure 26.1 (A) Overall survival of patients with the common subtypes of per...Figure 26.2 Five‐year survival rates in different histological subtypes from...
18 Chapter 28Figure 28.1 Organizational structure of the the Global T‐cell Lymphoma Conso...Figure 28.2 Clinical trial concept evaluation.Figure 28.3 Safety reporting for the Global T‐cell Lymphoma Consortium (FDA,...
1 Cover
2 Table of Contents
3 Begin Reading
1 iii
2 iv
3 xix
4 xx
5 xxi
6 xxii
7 xxiv
8 1
9 3
10 4
11 5
12 6
13 7
14 8
15 9
16 10
17 11
18 12
19 13
20 14
21 15
22 16
23 17
24 18
25 19
26 20
27 21
28 22
29 23
30 24
31 25
32 26
33 27
34 28
35 29
36 30
37 31
38 32
39 33
40 34
41 35
42 36
43 37
44 38
45 39
46 40
47 41
48 42
49 43
50 44
51 45
52 47
53 48
54 49
55 50
56 51
57 52
58 53
59 54
60 55
61 57
62 59
63 60
64 61
65 62
66 63
67 64
68 65
69 66
70 67
71 68
72 69
73 70
74 71
75 72
76 73
77 74
78 75
79 76
80 77
81 78
82 79
83 80
84 81
85 82
86 83
87 84
88 85
89 86
90 87
91 88
92 89
93 91
94 92
95 93
96 94
97 95
98 96
99 97
100 98
101 99
102 100
103 101
104 102
105 103
106 105
107 107
108 108
109 109
110 110
111 111
112 112
113 113
114 114
115 115
116 116
117 117
118 118
119 119
120 120
121 121
122 122
123 123
124 124
125 125
126 126
127 127
128 128
129 129
130 130
131 131
132 132
133 133
134 134
135 135
136 136
137 137
138 138
139 139
140 140
141 141
142 142
143 143
144 144
145 145
146 146
147 147
148 148
149 149
150 150
151 151
152 152
153 153
154 154
155 155
156 156
157 157
158 159
159 160
160 161
161 162
162 163
163 164
164 165
165 166
166 167
167 168
168 169
169 170
170 171
171 172
172 173
173 175
174 176
175 177
176 178
177 179
178 180
179 181
180 182
181 183
182 184
183 185
184 186
185 187
186 188
187 189
188 190
189 191
190 192
191 193
192 194
193 195
194 196
195 197
196 198
197 199
198 200
199 201
200 203
201 204
202 205
203 206
204 207
205 208
206 209
207 210
208 211
209 212
210 213
211 214
212 215
213 216
214 217
215 218
216 219
217 220
218 221
219 222
220 223
221 225
222 226
223 227
224 228
225 229
226 230
227 231
228 232
229 233
230 234
231 235
232 236
233 237
234 238
235 239
236 240
237 241
238 242
239 243
240 244
241 245
242 246
243 247
244 248
245 249
246 250
247 251
248 252
249 253
250 254
251 255
252 256
253 257
254 258
255 259
256 260
257 261
258 262
259 263
260 264
261 265
262 266
263 267
264 268
265 269
266 271
267 272
268 273
269 274
270 275
271 276
272 277
273 278
274 279
275 280
276 281
277 282
278 283
279 284
280 285
281 286
282 287
283 288
284 289
285 290
286 291
287 292
288 293
289 294
290 295
291 296
292 297
293 298
294 299
295 300
296 301
297 302
298 303
299 304
300 305
301 306
302 307
303 308
304 309
305 310
306 311
307 312
308 313
309 314
310 315
311 316
312 317
313 318
314 319
315 320
316 321
317 322
318 323
319 324
320 325
321 326
Читать дальше